Estrella Biopharma and TradeUP Acquisition today announced a definitive business combination agreement that would give the merged enterprise a pro forma valuation of $398.5 million.
If approved, at closing newly renamed Estrella Immunopharma would trade on the Nasdaq.
Estimated cash proceeds are expected to consist of TradeUP’s approximately $45.4 million of cash in trust (assuming no redemptions).
Estrella is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS®️ T-cell therapies under certain license agreements with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Read more.
